AavantiBio Appoints Dr. Christopher Wright as Chief Medical Officer

Print Friendly, PDF & Email

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Christopher Wright, M.D., Ph.D., as Chief Medical Officer. A neurologist and neuroscientist, Dr. Wright brings to AavantiBio more than 20 years of medical research and drug development experience in specialty and CNS orphan diseases, including cystic fibrosis, dementias, epilepsy, mitochondrial diseases, and sickle cell disease.

To read the full article, click here.